Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice

OBJECTIVE: Angiopoietin-2 (Ang-2) blocking agents are currently undergoing clinical trials for use in cancer treatment. Ang-2 has also been associated with rupture-prone atherosclerotic plaques in humans, suggesting a role for Ang-2 in plaque stability. Despite the availability of Ang-2 blocking age...

Descripción completa

Detalles Bibliográficos
Autores principales: Theelen, Thomas L., Lappalainen, Jari P., Sluimer, Judith C., Gurzeler, Erika, Cleutjens, Jack P., Gijbels, Marion J., Biessen, Erik A.L., Daemen, Mat J.A.P., Alitalo, Kari, Ylä-Herttuala, Seppo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549395/
https://www.ncbi.nlm.nih.gov/pubmed/26062989
http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549395/
https://www.ncbi.nlm.nih.gov/pubmed/26062989
http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.018

Ejemplares similares